

9 Literaturverzeichnis

1. Ahmad A, Hanby A, Dublin E, Poulsom R, Smith P, Barnes D, Rubens R, Anglard P, Hart I. Stromelysin-3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression; *Am J Pathol* 1998; 152(3):721-728
2. Akimoto S. Ultrasonic diagnosis of hepatic diseases; *Surg Gastroenterol* 1992; 15:1981-1990
3. Alvarez OA, Carmichael DF, DeClerck YA. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases; *J Natl Cancer Inst* 1990; 82:589-595
4. Amin Z, Bown SG, Lees WR. Local treatment of colorectal liver metastases: a comparison of interstitial laser photocoagulation (ILP) and percutaneous alcohol injection (PAI); *Clin Radiol* 1993; 48:166-171
5. Aparicio T, Kermorgant S, Dessirier V, Lewin MJM, Lehy T. Matrix metalloproteinase inhibition prevents colon cancer peritoneal carcinomatosis development and prolongs survival in rats; *Carcinogenesis* 1999; 20(8):1445-1451
6. Arlt M, Kopitz C, Pennington C, Watson KL, Krell HW, Bode W, Gansbacher B, Khokha R, Edwards DR, Kruger A. Increase in gelatinase-specificity of matrix metalloproteinase inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model; *Cancer Res* 2002; 62(19):5543-5550
7. Bärlocher F. *Biostatistik*; Thieme Verlag 1999;
8. Becker N, Wahrendorf J In: Becker N, Wahrendorf J. (Hrsg) *Krebsatlas der Bundesrepublik Deutschland; Atlas of cancer mortality in the Federal Republic of Germany*. Springer, Berlin; 1998
9. Bengmark S. Palliativ treatment of hepatic tumours; *Br J Surg* 1989; 76:771-773
10. Borner M, Castiglione M, Triller J, Baer HU, Soucek M, Blumgart L, Brunner K. Considerable side effect of chemoembolization for colorectal carcinoma metastatic to the liver; *Ann Oncol* 1992; 3:113-115
11. Braasch D, Zoedler T, Röher HD. A method to perfuse liver metastases with heated blood (45 °C, 45 min); *Cancer Res Clin Oncol* 1996; 122:67-69

12. Bramhall SR, Stamp GW, Dunn J, Lemoine NR, Neoptolemos JP. Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteases (TIMP1) in pancreatic and ampullary disease; *Br J Cancer* 1996; 73(8):972-978
13. Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Roschenthaler GV, Hadar R, Reich R. Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids; *J Med Chem* 2004; 47(11):2826-2832
14. Brown PD. Clinical studies with matrix metalloproteinase inhibitors; *APMIS* 1999; 107:174-180
15. Brown PD, Bloxidge RE, Stuart NS, Gatter KC, Carmichael J. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma; *J Natl Cancer Inst* 1993; 85(7):574-578
16. Canete-Soler R, Litzky L, Lubensky I, Muschel RJ. Localization of the 92 kd gelatinase mRNA in squamous cell and adenocarcinomas of the lung using in situ hybridization; *Am J Pathol* 1994; 144(3):518-527
17. Caster WO, Poncelet J, Simon AB, Armstrong WD. Tissue weights of the rat; I. Normal values determined by dissection and chemical methods; *Proc Soc Exp Biol Med* 1956; 91:122-126
18. Chambers AF, Matrisian L. Changing views of the role of matrix metalloproteinases in metastasis; *J Natl Cancer Inst* 1997; 89:1260-1270
19. Charnley RM, Doran J, Morris DL. Cryotherapy for liver metastases: a new approach; *Br J Surg* 1989; 76:1040-1041
20. Chiappa A, Zbar AP, Biella F, Staudacher C. Survival after repeat hepatic resection for recurrent colorectal metastases; *Hepatogastroenterology* 1999; 46(26):1065-1070
21. Daniel C, Duffield J, Brunner T, Steinmann-Niggli K, Lods N, Marti HP. Matrix metalloproteinase inhibitors cause cell cycle arrest and apoptosis in glomerular mesangial cells; *J Pharmacol Exp Ther* 2001; 297(1):57-68
22. Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR. Activity of type IV collagenases in benign and malignant breast disease; *Br J Cancer* 1993; 67(5):1126-1131

23. de Jong KP, Lont HE, Bijma AM, Brouwers MA, de Vries EG, van Veen ML, Marquet RL, Sloof MJ, Terpstra OT. The effect of partial hepatectomy on tumor growth in rats: in vivo and in vitro studies; *Hepatology* 1995; 22(4 Pt 1):1263-1272
24. Denis LJ, Verweij J. Matrix metalloproteinases inhibitors: present achievements and future prospects; *Invest New Drugs* 1997; 15:175-185
25. Doci R, Gennari L, Bignami P, Montalto F, Morabito A, Bozzetti F. One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of prognostic determinants; *Br J Surg* 1991; 78:797-801
26. Dritschilo A, Harter KW, Thomas D, Nauta R, Holt R, Lee TC, Rustgi S, Rodgers J. Intraoperative radiation therapy of hepatic metastases: technical aspects and report of a pilot study; *Int J Radiat Oncol Biol Phys* 1988; 14:1007-1011
27. Eder M, Weiss M. Hämatogene Lebermetastasen - humanpathologische Grundlagen; *Chirurg* 1991; 62:705-709
28. Elias D. Impact of tumor doubling time on the therapeutic strategy: application to so-called synchronous metastases of colorectal cancers; *Ann Chir* 1998; 52(5): 413-420
29. Felkel C, Scholl U, Mader M, Schwartz P, Felgenhauer K, Hardeland R, Beuche W, Weber F. Migration of human granulocytes through reconstituted basement membrane is not dependent on matrix metalloproteinase-9 (MMP-9); *J Neuroimmunol* 2001; 116(1):49-55
30. Fishman DA, Bafetti LM, Stack MS. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells; *Invasion Metastasis* 1996; 16(3):150-159
31. Foda HD, Zucker S. Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis; *Drug Discov Today* 2001; 6(9):478-482
32. Folkman J. Tumor angiogenesis and tissue factor; *Nat Med* 1996; 2(2):167-168
33. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases; *Ann Surg* 1999 Sep; 230(3):309-318; discussion 318-321
34. Fong Y, Kemeny N, Paty P, Blumgart LH, Cohen AM. Treatment of colorectal cancer; hepatic metastasis. *Semin Surg Oncol* 1996; 12:219-252

35. Fortner JG, Silva JS, Golbey RB, Cox EB, MacLean BJ. Multivariate analysis of a personal series of 274 consecutive patients with liver metastases from colorectal cancer. I. Treatment by hepatic resection . *Ann Surg* 1984; 199:306-316
36. Fujii H, Nakajima M, Aoyagi T, Tsuruo T. Inhibition of tumor cell invasion and matrix degradation by Aminopeptidase inhibitors; *Biol Pharm Bull* 1996; 19(1):6-10
37. Gallegos NC, Smales C, Savage FJ, Hembry RM, Boulos PB. The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer; *Surg Oncol* 1995; 4(2):111-119
38. Gray BN, Anderson JE, Burton MA, van Hazel G, Codde J, Morgan C, Klemp P. Regression of liver metastases following treatment with Yttrium-90 microspheres; *N Z J Surg* 1992; 62:105-110
39. Gress TM, Muller-Pillasch F, Lerch MM, Friess H, Buchler M, Adler G. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer; *Int J Cancer* 1995; 62(4):407-413
40. Grigioni WF, D'Errico A, Fiorentino M, Baccharini P, Onisto M, Caenazzo C, Stetler-Stevenson WG, Garbisa S, Mancini AM. Gelatinase A (MMP-2) and its mRNA detected in both neoplastic and stromal cells of tumors with different invasive and metastatic properties; *Diagn Mol Pathol* 1994; 3(3):163-169
41. Guenther U, Herbst H, Bauer M, Isbert C, Buhr HJ, Riecken EO, Schuppan D. Collagen type XVIII/endostatin is differentially expressed in primary and metastatic colorectal cancers and ovarian carcinomas; *Br J Cancer* 2001; 85:1540-1545
42. Hachisu M, Hiranuma T, Murata S, Aoyagi T, Umezawa H. Analgesic effect of Actinonin, a new potent inhibitor of multiple enkephalin degrading enzymes; *Life Science* 1987; 41:235-240
43. Hamdy FC, Fadlon EJ, Cottam D, Lawry J, Thurrell W, Silcocks PB, Anderson JB, Williams JL, Rees RC. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia; *Br J Cancer* 1994; 69(1):177-182
44. Hebel R, Stromberg MW. In: Hebel R, Stromberg MW (Hrsg) *Anatomy and embryology of the laboratory rat*; BioMed Verlag, Würthersee 1986

45. Henriët P, Blavier L, Declerck YA. Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation; *APMIS* 1999; 107:111-119
46. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy; *J Natl Cancer Inst* 2001; 93(3):178-193
47. Hughes K, Simon R, Songhorabodi S, Adson MA, Ilstrup DM, Fortner JG. Resektion of the liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection; *Surgery* 1988; 103:278-288
48. Hughes KS, Simon R, Songhorabodi S, Adson MA, Ilstrup DM, Fortner JG, MacLean BJ, Foster JH, Daly JM, Fitzherbert D. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence; *Surgery* 1986; 100(2):278-284
49. Isbert C, Boerner A, Ritz JP, Schuppan D, Buhr HJ, Germer CT. In situ ablation of experimental liver metastases delays and reduces residual intrahepatic tumour growth and peritoneal tumour spread compared with hepatic resection; *Br J Surg* 2002 Oct; 89(10):1252-1259
50. Isbert C, Ritz JP, Thompsen-Mund K, Schuppan D, Buhr HJ, Germer CT. Die in-situ-Ablation (LITT) experimenteller Lebermetastasen induziert im Vergleich zur chirurgischen Resektion eine erhöhte mRNA Expression von TIMP-1 in residualen unbehandeltem Tumor mit konsekutiv vermindertem Metastasenwachstum; *Z Gastroenterol* 2002; 40:670
51. Jankovic BD, Veljic J, Pesic G, Maric D. Enkephalinase-inhibitors modulate immune responses; *Intern J Neuroscience* 1991; 59:45-51
52. Jatzko GR, Lisborg PH, Stettner HM, Klimpfinger MH. Hepatic resection for metastases from colorectal carcinoma - a survival analysis. *Eur J Cancer* 1995; 31:41-46
53. Jia MC, Schwartz MA, Sang QA. Suppression of human microvascular endothelial cell invasion and morphogenesis with synthetic matrixin inhibitors. Targeting angiogenesis with MMP inhibitors; *Adv Exp Med Biol* 2000; 476:181-194
54. John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis; *Pathol Oncol Res* 2001; 7(1):14-23
55. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion; *Ann Med* 1999; 31:34-45

56. Kemeny N. Review of regional therapy of liver metastases in colorectal cancer; *Semin Oncol* 1992; 19:155-162
57. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis; *Cancer Chemother Pharmacol* 1999; 43 Suppl:42-51
58. Kodate M, Kasai T, Hashimoto H, Yasumoto K, Iwata Y, Manabe H. Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung; *Pathol Int* 1997; 47(7):461-469
59. Koshiha T, Hosotani R, Wada M, Fujimoto K, Lee JU, Doi R, Arii S, Imamura M. Detection of matrix metalloproteinase activity in human pancreatic cancer; *Surg Today* 1997; 27(4):302-304
60. Kurizaki T, Toi M, Tominaga T. Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma; *Oncol Rep* 1998; 5(3):673-677
61. Lambert E, Dasse E, Haye B, Petitfrere E. TIMPs as multifacial proteins; *Crit Rev Oncol Hematol* 2004 Mar; 49(3):187-198
62. Levin JJ, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS. The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines; *Bioorg Med Chem Lett* 2001; 11(22):2975-2980
63. Livraghi T, Lazzaroni S, Meloni F, Torzillig G, Vettori C. Intralesional ethanol in the treatment of unresectable liver cancer; *World J Surg* 1995; 19:801-806
64. Liotta LA. Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture; *Cancer Res* 1986; 46(1):1-7
65. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen; *Nature* 1980; 284(5751):67-68
66. Löffler G, Petrides PE. *Biochemie und Pathobiochemie*; Springer Verlag, Berlin, Heidelberg, New York 1997

67. Lozonschi L, Sunamura M, Kobari M, Egawa S, Ding L, Matsuno S. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models; *Cancer Res* 1999; 59(6):1252-1258
68. Maekawa R, Maki H, Wada T, Yoshida H, Nishida-Nishimoto K, Okamoto H, Matsumoto Y, Tsuzuki H, Yoshioka T. Anti-metastatic efficacy and safety of MMI-166, a selective matrix metalloproteinase inhibitor; *Clin Exp Metastasis* 2000; 18(1):61-66
69. Maquoi E, Munaut C, Colige A, Lambert C, Frankenne F, Noel A, Grams F, Krell HW, Foidart JM. Stimulation of matrix metalloproteinase-9 expression in human fibrosarcoma cells by synthetic matrix metalloproteinase inhibitor; *Exp Cell Res* 2002; 275(1):110-121
70. Maquoi E, Sounni NE, Devy L, Olivier F, Frankenne F, Krell HW, Grams F, Foidart JM, Noel A. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivate, an orally active and selective matrix metalloproteinases inhibitor; *Clin Cancer Res* 2004; 10(12 Pt 1): 4038-4047
71. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling; *Trends Genet* 1990; 6(4):121-125
72. Matsuoka T, Yashiro M, Sawada T, Ishikawa T, Ohira M, Chung KH. Inhibition of invasion and lymph node metastasis of gastrointestinal cancer cells by R-94138, a matrix metalloproteinase inhibitor; *Anticancer Res* 2000; 20(6B):4331-4338
73. McCarter MD, Fong Y. Metastatic liver tumors; *Semin Surg Oncol* 2000; 19(2): 177-188
74. McDonnell S, Navre M, Coffey RJ Jr, Matrisian LM. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinoma; *Mol Carcinog* 1991; 4(6):527-533
75. Minagawa M, Makuuchi M, Torzilli G, Takayama T, Kawasaki S, Kosuge T, Yamamoto J, Imamura H. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results; *Ann Surg* 2000; 231(4):487-499
76. Mizutani J, Hiraoka T, Yamashita R, Miyauchi Y. Promotion of hepatic metastases by liver resection in the rat; *Br J Cancer* 1992; 65(6):794-797

77. Möller PH, Ivarsson K, Stenram U, Randnell M, Tranberg KG. Comparison between interstitial laser thermotherapy and excision of an adenocarcinoma transplanted into rat liver; *Br J Cancer* 1998; 77:1884-1892
78. Momiyama N, Koshikawa N, Ishikawa T, Ichikawa Y, Hasegawa S, Nagashima Y, Mitsunashi M, Miyazaki K, Shimada H. Inhibitory effect of matrilysin antisense oligonucleotides on human colon cancer cell invasion in vitro; *Mol Carcinog* 1998; 22(1):57-63
79. Montironi R, Lucarini G, Castaldini C, Galluzzi CM, Biagini G, Fabris G. Immunohistochemical evaluation of type IV collagenase (72-kd metalloproteinase) in prostatic intraepithelial neoplasia; *Anticancer Res* 1996; 16(4A):2057-2062
80. Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinases in colorectal cancer progression and metastasis; *Biochim Biophys Acta* 2004 Dec; 17;1705(2):69-89
81. Moses O, Nemcovsky CE, Tal H, Zohar R. Tetracycline modulates collagen membrane degradation in vitro; *J Periodontol* 2001; 72(11):1588-1593
82. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer; *J Pathol* 1998; 185(3):256-261
83. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Matrix Metalloproteinase-1 is associated with poor prognosis in colorectal cancer; *Nature Med* 1996; 2:461-462
84. Nakagawa H, Yagihashi S. Expression of type IV collagen and its degrading enzymes in squamous cell carcinoma of lung; *Jpn J Cancer Res* 1994; 85(9):934-938
85. Nanko M, Shimada H, Yamaoka H, Tanaka K, Masui H, Matsuo K, Ike H, Oki S, Hara M. Micrometastatic colorectal cancer lesions in the liver; *Jpn J Surg* 1998; 28:707-713
86. Nawrocki B, Polette M, Marchand V, Monteau M, Gillery P, Tournier JM, Birembaut P. Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantitative and morphological analyses; *Int J Cancer* 1997; 72(4):556-564
87. Naylor MS, Stamp GW, Davies BD, Balkwill FR. Expression and activity of MMPS and their regulators in ovarian cancer; *Int J Cancer* 1994; 58(1):50-56

88. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: Biologic Activity and clinical Implications; *J of Clinical Oncol* 2000; 18(5):1135-1149
89. Nielsen BS, Sehested M, Kjeldsen L, Borregaard N, Rygaard J, Dano K. Expression of matrix metalloproteinase-9 in vascular pericytes in human breast cancer; *Lab Invest* 1997; 77(4):345-355
90. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, Jaeck D. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. *Association Francaise de Chirurgie. Cancer* 1996; 77(7):1254-1262
91. Ollis WD, East AJ, Gordon JJ, Sutherland IO. In I.A.M. Symposium on Microbiology, Chemistry of Microbial Product; The Microbial Research Foundation, Tokyo 1964; 6:204-214
92. Pajouh MS, Nagle RB, Breathnach R, Finch JS, Brawer MK, Bowden GT. Expression of metalloproteinase genes in human prostate cancer; *J Cancer Res Clin Oncol* 1991; 117(2):144-150
93. Pickren JW, Tsukuda Y, Lane WW. Liver metastases: analysis of autopsy data; In: Weiss L (Hrsg); *Liver metastasis*. Hall, Boston; 1984; 1-18
94. Polette M, Gilbert N, Stas I, Nawrocki B, Noel A, Remacle A, Stetler-Stevenson WG, Birembaut P, Foidart M. Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy; *Virchows Arch* 1994; 424(6): 641-645
95. Poulson R, Pignatelli M, Stetler-Stevenson WG, Liotta LA, Wright PA, Jeffery RE, Longcroft JM, Rogers L, Stamp GW. Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia; *Am J Pathol* 1992; 141(2):389-396
96. Pyke C, Ralfkiaer E, Tryggvason K, Dano K. Messenger RNA for two type IV collagenase is located in stromal cells in human colon cancer; *Am J Pathol* 1993; 142(2):359-365
97. Rabbani SA, Harakidas P, Guo Y, Steinman D, Davidsen SK, Morgan DW. Synthetic inhibitor of matrix metalloproteases decreases tumor growth and metastases in a syngeneic model of rat prostate cancer in vivo; *Int J Cancer* 2000; 87(2):276-282

98. Rashidi B, An Z, Sun FX, Sasson A, Gamagammi R, Moossa AR, Hoffman RM. Minimal liver resection strongly stimulates the growth of human colon cancer in the liver of nude mice; *Clin Exp Metastasis* 1999; 17(6):497-500
99. Ray JM, Stetler-Stevenson WG. Gelatinase A activity directly modulates melanoma cell adhesion and spreading; *EMBO J* 1995; 14:908-917
100. Remacle AG, Noel A, Duggan C, McDermott E, O'Higgins N, Foidart JM, Duffy MJ. Assay of matrix metalloproteinases type 1, 2, 3 and 9 in breast cancer; *Br J Cancer* 1998; 77(6):926-931
101. Rha SY, Yang WI, Kim JH, Min JS, Lee KS, Kim BS, Chung HC. Different expression patterns of MMP-2 and MMP-9 in breast cancer; *Oncol Rep* 1998; 5(4):875-879
102. Roche Lexikon Medizin; Urban & Fischer, 5. Auflage 2003
103. Saiki I, Fujii H, Yoneda J, Abe F, Nakajima M, Tsuruo T, Azuma I. *Int J Cancer* 1993; 54:137-143
104. Sayama K, Goto Y, Iguchi T, Takeda Y, Matsuzawa A. Effects of an antibiotic protease inhibitor, actinonin on the growth within collagen gels of non-metastatic and metastatic mouse mammary tumors of the same origin; *Cancer Letters* 1995;94:171-177
105. Scheele J, Altendorf-Hofmann A, Grube T, Hohenberger W, Stangl R, Schmidt K. Resection of colorectal liver metastases. What prognostic factors determine Patient selection? *Chirurg* 2001; 72(5):547-560
106. Scheele J, Stangl R, Schmidt K, Altendorf-Hofmann A. Recurrent tumor after R0 - resection of colorectal liver metastases. Incidence, resectability and prognosis; *Chirurg* 1995; 66(10):965-973
107. Sedlaczek N, Jia JD, Bauer M, Herbst H, Ruehl M, Hahn EG, Schuppan D. Proliferating bile duct epithelial cells are a major source of connective tissue growth factor in rat biliary fibrosis; *Am J Pathol* 2001; 158(4):1239-1244
108. Sherman DM, Wechselbaum RE, Order SE, Cloud L, Trey C, Piro AJ. Palliation of hepatic metastasis; *Cancer* 1978; 44:2013-2017
109. Slooter GD, Marquet RL, Jeekel J, Ijzermans JN. Tumor growth stimulation after partial hepatectomy can be reduced by treatment with tumour necrosis factor alpha; *Br J Surg* 1995; 82(1):129-132

110. Soini Y, Paakko P, Autio-Harminen H. Genes of laminin B1 chain, alpha 1 (IV) chain of type IV collagen, and 72-kd type IV collagenase are mainly expressed by the stromal cells of lung carcinomas; *Am J Pathol* 1993; 142(5):1622-1630
111. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases; *Lancet* 1994; 343:1405-1410
112. Stearns ME, Stearns M. Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a) expression in human prostate cancer; *Oncol Res* 1996; 8(2):63-67
113. Stearns ME, Wang M. Type IV collagenase (Mr 72,000) expression in human prostate: benign and malignant tissue; *Cancer Res* 1993; 53(4):878-883
114. Sugarbaker PH, Kemeny N. Metastatic cancer to the liver; *Adv Surg* 1989; 22: 1-56
115. Takeha S, Fujiyama Y, Bamba T, Sorsa T, Nagura H, Ohtani H. Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect; *Jpn J Cancer Res* 1997; 88(1):72-81
116. Taylor I. Liver metastases from colorectal cancer: lessons from past and present clinical studies; *Br J Surg* 1996; 83:456-460
117. Teronen O, Heikkila P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, Teronen A, Maisi P, Sorsa T. MMP inhibition and downregulation by bisphosphonates; *Ann N Y Acad Sci* 1999; 878:453-465
118. Thewes M, Pohlmann G, Atkinson M, Mueller J, Putz B, Hofler H. Stromelysin-3 (ST-3) mRNA expression in colorectal carcinomas. Localization and clinicopathologic correlations; *Diagn Mol Pathol* 1996; 5(4):284-290
119. TNM Klassifikation maligner Tumoren; Springer Verlag, 6. Auflage 2002
120. Tolnay E, Wiethage T, Kuhnen C, Wulf M, Voss B, Muller KM. Expression of type IV collagenase correlates with the expression of vascular endothelial growth factor in primary non-small cell lung cancer; *J Cancer Res Clin Oncol* 1997; 123(11-12):652-658
121. Tonn JC, Kerkau S, Hanke A, Bouterfa H, Mueller JG, Wagner S, Vince GH, Roosen K. Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro; *Int J Cancer* 1999; 80(5):764-772

122. Umezawa H, Aoyagi T, Tanaka T, Suda H, Okuyama A, Naganawa H, Hamada M, Takeuchi T. *J Antibiotics* 1985; 38:1629-1630
123. van Dale P, Galand P. Effect of partial hepatectomy on experimental liver invasion by intraportally injected colon carcinoma cells in rats; *Invasion metastasis* 1988; 8(4):217-227
124. Viadana E, Bross IDJ, Pickren JW. Cascade spread of blood-borne metastases in solid and nonsolid cancer of humans; In: Weiss L; Gilbert HA (Hrsg) *Pulmonary metastasis*. Hall, Boston; 1978; 143
125. Voet D, Voet JG. *Biochemie*; VCH Verlagsgesellschaft, Weinheim 1994;
126. Waas ET, Wobbes T, Lomme RM, DeGroot J, Ruers T, Hendriks T. Matrix metalloproteinase-2 and -9 activity in patients with colorectal cancer liver metastases; *Br J Surg* 2003; 90:1556-1564
127. Wagner JS, Adson MA, van Heerden JA, Adson MH, Ilstrup DM. The natural history of hepatic metastases from colorectal cancer; *Ann Surg* 1984; 199: 502-508
128. Walther HE. In: Walther HE (Hrsg) *Krebsmetastasen*; Schwabe, Basel; 1948
129. Weaver ML, Ashton JG, Zemel R. Treatment of colorectal liver metastases by cryotherapy; *Semin Surg Oncol* 1998; 14(2):163-170
130. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors; *Invest New Drugs* 1997; 15:61-75
131. Wolf K, Mazo I, Leung H, Engelke K, von Adrian UH, Deryugina EI, Strongin AY, Bröcker EB, Friedl P. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis; *J Cell Biol* 2003; 160(2):267-277
132. Wood M, Fudge K, Mohler JL, Frost AR, Garcia F, Wang M, Stearns ME. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer; *Clin Exp Metastasis* 1997; 15(3):246-258
133. Xu Y, Lai LT, Gabrilove JL, Scheinberg DA. Antitumor activity of Actinonin in vitro and in vivo; *Clin Cancer Research* 1998; 4:171-176

134. Yamauchi T, Watanabe M, Hasegawa H, Nishibori H, Ishii Y, Tatematsu H, Yamamoto K, Kubota T, Kitajima M. The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer; *Anticancer Res* 2003; 23(1A):245-249
135. Yao M, Lam EC, Kelly CR, Zhou W, Wolfe MM. Cyclooxygenase-2 selective inhibition with NS-398 suppress proliferation and invasiveness and delays liver metastasis in colorectal cancer; *Br J Cancer* 2004; 90(3):712-719
136. Young TN, Rodriguez GC, Rinehart AR, Bast RC Jr, Pizzo SV, Stack MS. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2; *Gynecol Oncol* 1996; 62(1):89-99
137. Zeng ZS, Guillem JG. Colocalisation of matrix metalloproteinase-9-mRNA and protein in human colorectal cancer stromal cells; *Br J Cancer* 1996; 74(8):1161-1167